Eli Lilly and Company (LLY) witnessed a selling pressure and the shares last traded with a loss of -0.09 points or -0.12% at $76.94. Investors jumped in to buy the shares on weakness. The net money flow till latest update was calculated at $8.42 million with an inflow of $53.88 million in upticks and an outflow of $45.46 million in downticks. Using the data, the up/down ratio is found to be 1.19. The share price has recorded 2.07% on a weekly basis.A block trade of $12.02 million in uptick and $2.23 million in downtick was also observed, resulting in an up/down ratio of 5.39. The net money flow of the block trade stood at a $9.78, signaling heavy buying.Block trades are executed by Investment Banking firms or Wealth Managers shifting positions or Day traders taking advantage of trading signals.
Shares of Eli Lilly and Company rose by 3.67% in the last five trading days and 5.51% for the last 4 weeks. Eli Lilly and Company is up 5.78% in the last 3-month period. Year-to-Date the stock performance stands at 5.51%. Eli Lilly and Company (NYSE:LLY) rose 0.74% or 0.57 points on Wednesday and made its way into the gainers of the day. After trading began at $77.9 the stock was seen hitting $78.57 as a peak level and $76.91 as the lowest level. The stock ended up at $77.6. The daily volume was measured at 4,959,227 shares. The 52-week high of the share price is $83.785 and the 52-week low is $64.18. The company has a market cap of $85,666 million.
Company has reported several Insider transactions to the SEC, on Dec 19, 2016, Endowment Inc Lilly (10% owner) sold 200,000 shares at 72.69 per share price.On Dec 19, 2016, Donald A Zakrowski (Chief Accounting Officer) sold 1,000 shares at 72.13 per share price.On Dec 19, 2016, Jackson P Tai (director) purchased 1,375 shares at 72.64 per share price.
Eli Lilly and Co Last issued its quarterly earnings results on Jan 31, 2017. The company reported $0.95 EPS for the quarter, missing the analyst consensus estimate by $ -0.03. Analyst had a consensus of $0.98. The company had revenue of $5760.50 million for the quarter, compared to analysts expectations of $5554.54 million. The companys revenue was up 7.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.78 EPS.
Several Stock Research Financial Advisors from Investment Banking firms have advised their client and investors on the stock.Eli Lilly and Co was Upgraded by Morgan Stanley to Overweight on Dec 16, 2016.
Eli Lilly and Company discovers, develops, manufactures, and sells products in one significant business segment -pharmaceutical products. The company directs its research efforts primarily toward the search for products to diagnose, prevent and treat human diseases. The company also conducts research to find products to treat diseases in animals and to increase the efficiency of animal food production.